Citations

Clear

1413 citation(s) found for "To, Christina".

0425 When the Day Starts with An Ache: Morning Headaches and Sleep Patterns in Women with Insomnia and Pain Complaints
Richardson, Marlee, Stearns, Melanie, Curtis, Ashley, Robinson, Michael, Staud, Roland, Craggs, Jason, Davenport, Mattina, Sahota, Pradeep, Chokkalingam, Siva, Berry, J.L. , McCrae, Christina, Stearns, Melanie , Robinson, Michael, Staud, Roland M. , Craggs, Jason G. , Davenport, Mattina , Sahota, Pradeep Kumar , Berry, Jasmine, McCrae, Christina S.

Mayo Clinic

SLEEPJ | May 9, 2026 | Volume: 49 | Issue: Supplement_1 | Pages: A189-A189

10.1093/sleep/zsag091.0425 Get It

Abstract Introduction Chronic and episodic headaches have a strong bidirectional relationship with insomnia and poor sleep outcomes. AM (morning) headaches are common among chronic pain populations, but additional research is needed to understand their pain experiences and potentially inform targeted interventions. Herein, we investigated whether presence of AM headaches is associated with differences in diary-based sleep parameters and pain ratings in women with pain and sleep complaints. We hypothesize individuals with AM headaches will have more sleep disturbances and fatigue as well as greater pain intensity and unpleasantness. Methods Women (N=293, Mage=39.59, SD 12.65, 65% with morning headaches) reporting insomnia and pain complaints (65% also reporting morning headaches) were recruited in mid-Missouri for an RCT (R01NR017168, ClinicalTrials.gov Identifier: NCT03744156). During baseline assessment, participants completed 2 weeks of daily electronic diaries and reported AM headache presence (Y/N). Independent samples t-tests (SPSS) evaluated differences in sleep parameters and pain ratings in those with and without AM headaches. Participants reporting diagnosed sleep apnea were excluded. Results Morning fatigue was higher among individuals with AM headaches (M=54.72+/-18.25) than those without (M=50.02+/-19.12), t(291)=-2.07, p=.04. Pain intensity was greater in the AM headache group in the morning (M=47.65+/-19.73 vs. M=42.52+/-21.91), t(291)=-2.04, p=.042, and evening, (M=49.62+/-19.10 vs. M=44.23+/-20.66), t(283)=-2.21, p=.028. Evening pain unpleasantness was also rated as higher among those with AM headaches (M=45.90+/-19.55) compared to those without (M=40.82+/-22.52), t(283)=-1.99, p=.048, but morning pain unpleasantness ratings only trended towards significance. Conclusion AM headaches can present as a chronic condition or as a symptom of other sleep disorders. Individuals with AM headaches had minimal sleep differences overall, but morning fatigue, pain intensity (AM and PM), and evening pain unpleasantness ratings were all significantly greater in those with AM headaches. Undiagnosed sleep disorders other than insomnia (i.e., obstructive sleep apnea) or other health concerns, like increased intracranial pressure, may have contributed to pain-related findings. Considering the high prevalence of COMISA in chronic pain populations, further investigation should examine its impact on sleep and headache severity. Support (if any) National Institute of Nursing Research (NR017168; Clinical trial: NCT03744156; PI: McCrae).
Targeting Hyperoxia‐Induced Cellular Senescence in Developing Human Airway Cells: Senomorphics Versus Senolytics Versus Antioxidants
Ngassie, Maunick Lefin Koloko, Drake, Li Y., Zhu, Yi, Ortiz, Yamillie , Pfeffer-Kleemann, Daniel A., Thompson, Michael A, Pabelick, Christina M., Prakash, Y S, Ngassie, Maunick Lefin Koloko , Koloko Ngassie, Maunick Lefin , Pfeffer-Kleemann, Daniel , Drake, Li Y. , Hamrick, Samantha K. , Pabelick, Christina M. , Prakash, Y. S.

Mayo Clinic

Aging Cell | May 8, 2026 | Volume: 25 | Issue: 5 | Pages: No page available

10.1111/acel.70538 | PMID 42101153 Get It

ABSTRACT Supplemental oxygen (hyperoxia), often provided to premature infants, can disrupt lung growth and contribute to development of neonatal and pediatric lung diseases, necessitating understanding of underlying mechanisms. We previously showed that even moderate hyperoxia (< 60% O 2 ) induces detrimental cellular senescence in 18–22 weeks human fetal airway smooth muscle (fASM), a key cell type in airway contractility and remodeling. In this study, we examined the ability of senotherapeutics Fucoidan and Dasatinib (D) + Quercetin (Q) (D + Q) to mitigate adverse effects of hyperoxia and assessed the preventive effect of mitochondrial antioxidants (MitoQ). fASM cells exposed to normoxia (21% O 2 ) or hyperoxia (50% O 2 ) were treated with Fucoidan [100 μg/mL], D + Q [250 nM + 375 nM] or MitoQ [100 nM] and assessed for senescence markers, senescence‐associated secretory profile (SASP), extracellular matrix (ECM) deposition, and cell viability. Our results showed that moderate hyperoxia increases senescence markers and SASP. Fucoidan decreased p21 expression and inhibited SASP release without inducing cell death, while D + Q decreased β‐galactosidase (β‐Gal) activity, p21 and plasminogen activator inhibitor‐1 (PAI‐1) expression, and caused cell death without affecting SASP in hyperoxia‐induced senescent fASM. MitoQ prevented increases in senescence markers and SASP in hyperoxia‐exposed fASM. These findings demonstrate distinct and viable strategies to counter hyperoxia‐induced fASM senescence. Fucoidan (senomorphic), D + Q (senolytic), and MitoQ (prophylactic antioxidant) represent promising, mechanistically different approaches to alleviate detrimental effects of moderate hyperoxia in developing airways towards limiting perinatal lung disease.
Tumor mutational and microbial profiles of early-onset and later-onset colorectal cancers according to detailed tumor location: an international pooled analysis
Ugai, Tomotaka, Ugai, Satoko , Qu, Conghui, Toland, Amanda E., French, Amy J. , Gsur, Andrea , Chan, Andrew T., Guelpen, Bethany van, Lynch, Brigid, Um, Caroline Y., Newton, Christina, Thomas, Claire E., Buchanan, Daniel D., Drew, David, Goode, Ellen L., Aglago, Elom K., Brenner, Hermann, Figueiredo, Jane C., Huyghe, Jeroen R., Nowak, Jonathan A., Doheny, Kimberly F., Hsu, Li, Boardman, Lisa, Gunter, Marc J., Giannakis, Marios, Jenkins, Mark A., Obon-Santacana, Mereia, Hoffmeister, Michael, Song, Mingyang, Murphy, Neil, Campbell, Peter T., He, Qianchuan, Trinh, Quang M., Pai, Rish K. , Steinfelder, Robert S. , Berndt, Sonja I., Gruber, Stephen B., Gallinger, Steven, Zaidi, Syed H., Hudson, Thomas J., Moreno, Victor, Sun, Wei, Huang, Wen-Yi, Lin, Yi, Cao, Yin, Peters, Ulrike, Hullar, Meredith, Phipps, Amanda I., Ugai, Tomotaka , Chen, Yu , Qu, Conghui , Chan, Andrew T , Um, Caroline Y. , Thomas, Claire E. , Buchanan, Daniel D. , Drew, David A. , Aglago, Elom K. , Brenner, Hermann , Figueiredo, Jane C. , Huyghe, Jeroen R. , Nowak, Jonathan A. , Doheny, Kimberly F. , Gunter, Marc J. , Giannakis, Marios , Jenkins, Mark A. , Obón‐Santacana, Mireia , Hoffmeister, Michael , Murphy, Neil , Georgeson, Peter , Campbell, Peter T., Trinh, Quang M. , Berndt, Sonja I. , Brezina, Stefanie , Gruber, Stephen B. , Gallinger, Steven , Zaidi, Syed H., Harrison, Tabitha A. , Hudson, Thomas J , Moreno, Victor , Sun, Wei, Huang, Wen‐Yi , Wang, Xiaoliang , Lin, Yi, Peters, Ulrike , Hullar, Meredith A.J. , Phipps, Amanda I. , Ogino, Shuji

Mayo Clinic

International Journal of Surgery | May 6, 2026 | Volume: 112 | Issue: 5 | Pages: 11070-11085

10.1097/js9.0000000000003877 Get It

Background: Considering the pathophysiological importance of the intestine-passing microbiota, we hypothesized that the mutational and microbial profiles of colorectal cancer might gradually change along detailed anatomical locations and that these trends might differ by the age of diagnosis and the microsatellite instability (MSI) status. Methods: We assessed somatic mutations and selected bacterial species in colorectal carcinomas along the cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum, utilizing targeted sequencing data ( N = 5685) from the Genetics and Epidemiology of Colorectal Cancer Consortium and tissue microbial data ( N = 1389) from the Health Professionals Follow-up Study and Nurses’ Health Study. Results: There were decreasing trends from the cecum to rectum in the prevalence of gene mutations in the IGF/PI3K, receptor tyrosine kinase (RTK)/RAS, TGFB, and WNT signaling pathways (all P trend < 0.0001), as well as high levels of Bacteroides fragilis ( P trend < 0.0001) and high levels of Fusobacterium nucleatum ( P trend = 0.0029) (but not enterotoxigenic Bacteroides fragilis or pks+ Escherichia coli ). Conversely, TP53 pathway mutations showed an increasing cecum-to-rectum trend ( P trend < 0.0001). Similar to later-onset cases diagnosed at ages 50 years and older, in early-onset cases diagnosed under the age of 50 years, we found generally decreasing cecum-to-rectum trends of IGF/PI3K, RTK/RAS, TGFB, and WNT pathway mutations and an increasing cecum-to-rectum trend in TP53 pathway mutations. By contrast, the cecum-to-rectum prevalence-changing trends in IGF/PI3K, RTK/RAS, TGFB, and TP53 pathway mutations were present in non–MSI-high tumors but not in MSI-high tumors (all P interaction < 0.0052). Conclusion: Non–MSI-high colorectal cancers exhibited decreasing cecum-to-rectum trends of IGF/PI3K, RTK/RAS, and TGFB pathway mutations (and an increasing trend of TP53 pathway mutations), in contrast to MSI-high tumors that demonstrated no such trends. Our study highlights the importance of detailed colorectal subsite information combined with tumor molecular and microbial characteristics in colorectal cancer research.
Risk Factors for Multiregional Spinal Column Injury
Hongsermeier-Graves, Natasha, Dantam, Christina, Eldredge, R.Scott, Kurudza, Elena, Larsen, Kezlyn, Swendiman, Robert A. , Rampton, John , Inaba, Kenji, Iyer, Rajiv R. , Brockmeyer, Douglas L. , Kelly, Michael P., Katsma, Mark S. , Russell, Katie W., Ravindra, Vijay M. , Ravindra, Vijay M , Hongsermeier-Graves, Natasha , Dantam, Christina R. , Kahan, Anastasia M , Eldredge, R Scott , Kurudza, Elena , Wan, Hsuan‐Yu , Inaba, Kenji , Kelly, Michael P. , Russell, Katie W.

Mayo Clinic

Spine | May 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/brs.0000000000005719 | PMID 42085693 Get It

Study Design. Subanalysis of a prospective, multicenter, observational study at 72 US adult, pediatric, and mixed trauma centers. Objective. We investigated trauma-related risk factors and patient-level factors associated with multiregional spinal column injury, defined as cervical spine injury (CSI) requiring treatment and thoracolumbar injury (TLI). Summary of Background Data. Traumatic spinal injury causes morbidity and mortality in pediatric patients. Injuries to multiple spinal column regions require early identification and thoughtful management. Methods. All children <18 years undergoing cervical spine evaluation after blunt multisystem trauma were prospectively identified and enrolled. Clinically significant CSI was defined by cervical spine surgery or halo placement. TLI incidence and management was recorded. The primary outcome was multiregional spinal column injury (CSI+TLI). Results. Of 19,651 enrolled patients, 1484 children (7.5%) experienced a TLI, 159 (0.81%) had CSI requiring treatment, and 30 (0.15%) had CSI+TLI. Multivariate analysis revealed that the trauma-related factors mechanism of injury ( P <0.001), rib fractures (odds ratio (OR) 2.8 [2.3-3.4]), hemothorax/pneumothorax (OR 2.0 [1.7-2.4]), bowel injury (OR 4.0 [2.9-5.4]), pelvic fracture (OR 1.5 [1.2-1.9]), and clinically significant CSI (OR 1.9 [1.2-2.9]) were independently associated with TLI. Of the 159 children with clinically significant CSI, 30 also experienced TLI (19%). Multivariate analysis identified prehospitalization intubation (OR 3.1 [1.1-8.4]) and rib fractures (OR 3.9 [1.2-12.8]) as independent associations with CSI+TLI. Conclusions. Of children with CSI requiring treatment, 19% experienced TLI. MOI and various trauma-related injuries were independently associated with TLI, whereas prehospitalization intubation and rib fractures were independent risk factors for CSI+TLI. These factors should trigger screening for multiregional spinal column injury in pediatric trauma patients. Furthermore, if there is known TLI, the cervical spine should be evaluated, and if there is significant CSI, then dedicated imaging of the thoracic and lumbar spine is indicated. Level of Evidence. III
At‐home visual acuity in children using a custom iPhone application compared with standardized in‐office visual acuity testing
Roberts, Tawna L. , Bothun, Erick D. , Zhu, Yufeng, Henderson, Robert J. , Boyle, Nicole M, Leske, David A. , Wernimont, Suzanne M., Marino, Carrie E, Manh, Vivian M. , Youngerman, Jillian M, Qayum, Jennifer N, Srinivasan, Gayathri , Titelbaum, Jenna R. , Crouch, Eric R. , Colburn, Jeffrey, Esposito, Christina , Zeto, V Lori, Connolly, Katie, Bhakta, Rita M, Lorenzana, Ingryd J., McDowell, Paula, Beaulieu, Wesley T, Kraker, Raymond T, Holmes, Jonathan M, Pineles, Stacy L., Weise, Katherine K., Cotter, Susan A, Group, Pediatric Eye Disease Investigator, Beaulieu, Wesley T , Kraker, Raymond T , Hatt, Sarah R. , Raghuram, Aparna , McDowell, Paula S., Kraker, Raymond T. , Holmes, Jonathan M. , Cotter, Susan A.

Mayo Clinic

Optometry and Vision Science | May 1, 2026 | Volume: 103 | Issue: 4 | Pages: No page available

10.1002/ovs2.70040 | PMID 42062237 Get It

ABSTRACT Purpose To validate a custom smartphone application for at‐home visual acuity (VA) measurement in children. Methods A total of 452 children aged 3–17.5 years participated. Certified examiners measured in‐office test–retest VA (logMAR) using gold‐standard Amblyopia Treatment Study HOTV (3‐to‐6‐year‐olds, younger cohort) or electronic Early Treatment of Diabetic Retinopathy Study (7‐to‐17.5‐year‐olds, older cohort) protocols at 3–4.5 m and app‐based VA at 1.5 m. Caregivers measured at‐home app‐based VA at 1.5 m. Results Comparing at‐home app‐based with gold‐standard VA, in eyes 20/40 or better, 95% (143/151) and 93% (91/98) of the younger and older cohorts were within 2 lines, respectively (mean differences: younger = −0.03, older = −0.04; 95% limits‐of‐agreement half‐width (LOA): younger = ±0.26, older = ±0.22). In eyes 20/50 or worse, 66% (42/64) and 75% (76/101) of the younger and older cohorts were within 2 lines, respectively (mean differences: younger = 0.11, older = 0.13, LOA: younger = ±0.50, older = ±0.51). Comparing in‐office app‐based VA with gold‐standard VA, in eyes 20/40 or better, 98% (160/164) and 94% (99/105) of the younger and older cohorts were within 2 lines, respectively (mean differences: younger = −0.03, older = −0.03; LOA: younger = ±0.22; older = ±0.24). In eyes 20/50 or worse, 85% (60/71) and 91% (101/111) of the younger and older cohorts were within 2 lines, respectively (mean differences: younger = 0.04; older = 0.04; LOA: younger = ±0.39; older = ±0.24). For gold‐standard test–retest, in eyes 20/40 or better, 99% (163/164) and 99% (104/105) of the younger and older cohorts had retest within 2 lines, respectively (mean differences: younger = 0.00; older = 0.01; LOA: younger = ±0.17; older = ±0.11). For 20/50 or worse, 92% (66/72) and 100% (111/111) in the younger and older cohorts were within 2 lines, respectively (mean differences: younger = 0.01; older = 0.02; LOA: younger = ±0.35; older = ±0.15). Conclusions Our app demonstrated good concordance with the gold standard at home and in the office for eyes with VA of 20/40 or better. However, concordance decreased considerably for eyes with VA 20/50 or worse, particularly at home.
PRO-ADD: Patient-empowered dose-finding trials integrating safety, preliminary efficacy and patient-reported outcomes for optimal dose selection
Alger, Emily , Mandrekar, Sumithra J. , Yin, Jun, Yap, Christina , Yap, Christina , Yin, Jun

Mayo Clinic

Statistical Methods in Medical Research | April 30, 2026 | Volume: 35 | Issue: 6 | Pages: 1177-1198

10.1177/09622802261435969 | PMID 42057418 Get It

Advances in oncology drug development are driving the emergence of novel therapies, challenging traditional dose-efficacy assumptions in dose-finding oncology trials. Traditional trial designs aim to identify a maximum tolerated dose (MTD) by assessing patients’ dose-limiting toxicities (DLTs) – adopting traditional dose-efficacy paradigms that efficacy increases with treatment dose. With these new therapies in mind, emphasis should shift toward methodological advancements in trial designs aimed at identifying optimal doses, rather than solely determining MTDs. Incorporating patient-reported outcomes (PROs) within dose-finding oncology trials is increasingly recommended to better understand treatments’ tolerability profiles, especially given the extended tolerability assessment windows for novel immunotherapies and targeted therapies. This article introduces PRO-ADD ( P atient- R eported O utcomes A ided D ose-optimisation D esign), a modular trial design framework for dose-optimisation. We leverage this framework to optimise dosage with respect to three key outcomes – clinician-assessed DLTs, PROs and preliminary efficacy. PRO-ADD performs well at identifying the optimal dose (both efficacious and tolerable) – successfully identifying the most tolerable effective dose and avoiding escalation to larger, safe doses offering no additional efficacy benefit. As the field evolves, patient-centric dose-finding approaches incorporating PROs are crucial in advancing our understanding of treatment tolerability, and in turn, shaping the future landscape of dose-finding oncology trials.
Addressing Skin Adverse Events during Mirdametinib Treatment in Patients with Neurofibromatosis Type 1-Associated Plexiform Neurofibromas: Guidance from Experts on the Management of MEK Inhibitor-Associated Skin AEs
Hirbe, A., Anadkat, M., Boull, C., Nickerson, M., Weber, M., Babovic-Vuksanovic, D., Gershon, T., Hirbe, Angela C. , Anadkat, Milan J. , Boull, Christina , Babovic‐Vuksanovic, Dusica , Gershon, Timothy R.

Mayo Clinic

Neuropediatrics | April 27, 2026 | Volume: 57 | Issue: No issue available | Pages: No page available

10.1055/s-0046-1822860 Get It

Multisite study: Predicting Lewy body disease using skin biopsy α-synuclein seed amplification assays
Janarthanam, Chelva, Hughson, Andrew G, Holzinger, David, Taylor, Keenan, Caughey, Byron, Adler, Charles H, Shill, Holly A, Mehta, SH, Driver-Dunckley, Erika, Ho, Andrew H, Shprecher, David R, Belden, Christine M. , Atri, Alireza, Zhang, Nan, Chen, Kewei, Serrano, Geidy E, Beach, T, Beach, Thomas G , Orru, Christina Doriana , Hughson, Andrew G. , Kanthasamy, Anumantha G. , Caughey, Byron W. , Heym, Roland G. , Adler, Charles H. , Shill, Holly A. , Mehta, Shyamal H. , Driver‐Dunckley, Erika , Choudhury, Parichita , Shprecher, David , Atri, A., Serrano, Geidy E. , Beach, Thomas G.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | April 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnen/nlag048 | PMID 42223057 Get It

Abstract Skin biopsies analyzed with α-synuclein seed amplification assays (SAAs) are a simple way to clinically interrogate the presence of α-synuclein aggregates. We determined the accuracy of skin biopsy SAA in predicting the clinical diagnoses of Parkinson disease (PD), PD with dementia (PDD) and dementia with Lewy bodies (DLB). Blinded SAAs were performed in 3 independent laboratories. Subjects diagnosed with PD, PDD and DLB were analyzed together as group 1, clinically unaffected subjects as group 2 and those with risk factors for LBD as group 3. Punch biopsies were taken from the posterior neck and analyzed by the 3 labs in 6 separate SAAs. Pairwise agreement between labs and assays ranged from excellent (kappa 0.82) to moderate (kappa 0.40-0.68). Sensitivity across assays ranged between 50.0% and 61.3%; specificity ranged between 68.6% and 100%. Comparisons of group 1 vs group 2 produced the greatest specificities, between 77.3% and 100%. In 17 cases that subsequently came to autopsy, 93% of SAAs were positive in those at the neocortical LBD stage but in only &lt;10% of those at lower stages. Skin biopsy α-synuclein SAA may be useful as a diagnostic and progression biomarker in Lewy body dementia clinical trials.
The validation of measured and self-reported sleep duration and perceived sleep quality: an empirical study with three generations of smartwatches
Saliba, Christina T. , Wilton, Angelina R. , Sheffield, Katharine, Wilkes, Quantia , Anacker, Miriam, Athreya, Arjun P. , Chesak, Sherry S. , Sheffield, Katharine, West, Colin P. , Croarkin, Paul E. , Dyrbye, Liselotte N. , Bobo, William V. , Chauhan, Mohit

Mayo Clinic

Frontiers in Psychiatry | April 20, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fpsyt.2026.1767216 | PMID 42088007 Get It

Introduction Sleep is routinely assessed in the management of mental health conditions. Wearable technologies like smartwatches offer a non-intrusive method to quantitatively measure sleep. However, there are limited empirical benchmarks for sleep duration and sleep quality measured by wearables against user reports. This study aims to evaluate the concordance between user-reported and smartwatch-measured hours of sleep and sleep quality. Methods Participants were recruited from two decentralized digital health well-being studies and completed a 7-day sleep diary while simultaneously wearing their smartwatch to sleep (November 7, 2023 - June 30, 2024). Participants self-reported sleep timestamps and perceived sleep quality using the Sleep Quality Scale. Sleep timestamps and quality were also derived from their smartwatches (Garmin Vívoactive 4 2019, Garmin Venu 2 Plus 2022, and Garmin Venu 3/3S 2023). Statistical analyses included paired t-tests, equipercentile linking, and chi-square tests to assess agreement between smartwatch and self-reported sleep parameters. Exploratory analyses established the difference between reported and recorded sleep duration in healthcare shift workers. Results From 841 sleep instances reported by 130 participants wearing three different generation smartwatches, the mean difference in sleep duration between smartwatch-recorded and participant-reported was 21.22 (Garmin Vívoactive), 11.67 (Garmin Venu 2 Plus), and 6.58 (Garmin Venu 3/3S) minutes, respectively. There were statistically significant between-group differences in mean sleep durations assessed by participant self-report vs. Vívoactive 4 smartwatches, but not self-report vs. Venu 2 Plus or Venu 3/3S smartwatches. Equipercentile linking revealed concordance between smartwatch sleep scores and self-reported sleep quality using the Sleep Quality Scale (SQS) between 4 and 7, with disagreements observed at the SQS ranges from 0–4 and 7-10. Conclusions These results suggest that wearables can reliably measure sleep duration, and future research warrants improvements in algorithms that estimate sleep quality with validations across different wearable vendors.
Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update
Chen, Alice P. , Rosenberger, Christina L. , Moore, Nancy, Foster, Jared C. , Naqash, Abdul Rafeh , Sharon, Elad , Coyne, Geraldine O’Sullivan , Schwartz, Gary K. , Riedel, Richard F. , Glod, John, Hu, James , Read, William L., Merriam, Priscilla , Deshpande, Hari A., Ladle, Brian H. , Okuno, Scott H. , Beck, Jill C., Chen, J Y, Ferry‐Galow, Katherine V., Fino, Kristin, Wilsker, Deborah, Begum, Asma , Parchment, Ralph E. , Doroshow, James H. , O'Sullivan Coyne, Geraldine , Conley, Anthony P , Burgess, Melissa A , Davis, Elizabeth J , Merriam, Priscilla , Ladle, Brian H , Okuno, Scott , Chen, James L , Ferry-Galow, Katherine V , Miller, Brandon L , Wilsker, Deborah F , Doroshow, James H , Riedel, Richard F , Sharon, Elad , Naqash, Abdul Rafeh , Schwartz, Gary K , Moore, Nancy, Glod, John , Conley, Anthony P. , Read, William, Burgess, Melissa , Davis, Elizabeth J. , Deshpande, Hari A.

Mayo Clinic

Journal of Clinical Oncology | April 18, 2026 | Volume: 44 | Issue: 16 | Pages: 1490-1497

10.1200/jco-25-02811 | PMID 41999612 Get It

We previously reported initial results of the pivotal phase II trial of atezolizumab for patients with alveolar soft part sarcoma (ASPS; ClinicalTrials.gov identifier: NCT03141684 ). Here, we report on three additional years of observation. Fifty-three patients with ASPS received atezolizumab. Median duration of response increased to 37.0 months. Objective response rate (ORR) and median progression-free survival (mPFS) remained essentially as previously reported (35.8% [95% CI, 23.1 to 50.2] and 20.8 months [IQR, 7.6-not reached], respectively). ASPSCR1::TFE3 fusion type was determined for 47/53 patients; ORR and mPFS were higher among the 41 patients expressing type 1 (43.9% [95% CI, 28.5 to 60.2] and 28.3 months [IQR, 9.2-not reached], respectively) than the six patients expressing type 2 (0% [95% CI, 0 to 45.9] and 7.5 months [IQR, 3.9-not reached], respectively, PFS HR, 3.2 [95% CI, 1.01 to 10.2]). Eleven patients chose a per-protocol drug holiday (range, 3.5-26.4 months) after ≥2 years of treatment; two experienced disease progression during the holiday. Nine eligible patients elected to receive bevacizumab plus atezolizumab after progressing on monotherapy; ORR was 0% and mPFS was 18.5 months (IQR, 7.9-21.1) in this small cohort. Long-term results support using atezolizumab to treat ASPS, even for several years; a drug holiday with careful monitoring may be an option for some patients.